The treatment of Helicobacter pylori infection includes of current standard triple therapies consisting of a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole on the basis of simplicity, safety, and efficacy. There are several factors determining the success of H. pylori eradication treatment. They include the components of a treatment regimen, the treatment duration, patient compliance, the presence of resistant or virulent strains of Helicobacter pylori and possibly the patient\u27s gastric acid secretory status. PPI, clarithromycin 500 mg, amoxicillin 1 g or metronidazol 400 mg, all given bid for 7 days are the most commonly used combination regimens. RBC-based triple therapies, furazolidone or rifabutin containing r...
Helicobacter pylori (H. pylori) is currently considered the most important exogenous factor in the g...
Over the past 30 years, multidrug regimens consisting of a proton pump inhibitor (PPI) and two or th...
Helicobacter pylori, a Gram-negative organism that survives in the deep mucus layer and attaches to ...
The treatment of Helicobacter pylori infection includes of current standard triple therapies consist...
The treatment of Helicobacter pylori infection includes of current standard triple therapies consist...
Th e most popular regimen for eradication of Helicobacter pylori (H. pylori) infection is triple the...
Fourteen-day triple therapy with a proton pump inhibitor (PPI) plus clarithromycin and either amoxic...
H. pylori is one of the most common commensal microorganisms in the human body, colonizing up to 60%...
line depends on the treatment initially used. If a clarithro-mycin-based regimen was administered in...
The eradication of Helicobacter pylori is at present widely recognized as the adequate therapeutic a...
AbstractEradication of Helicobacter pylori infection has become an important issue recently, because...
Over the past 30 years, multidrug regimens consisting of a proton pump inhibitor (PPI) and two or th...
Helicobacter pylori infection, which is present in 30-60% of the population in developed countries a...
Over the past 30 years, multidrug regimens consisting of a proton pump inhibitor (PPI) and two or th...
Helicobacter pylori infection has many different clinical outcomes. Not all infected persons need to...
Helicobacter pylori (H. pylori) is currently considered the most important exogenous factor in the g...
Over the past 30 years, multidrug regimens consisting of a proton pump inhibitor (PPI) and two or th...
Helicobacter pylori, a Gram-negative organism that survives in the deep mucus layer and attaches to ...
The treatment of Helicobacter pylori infection includes of current standard triple therapies consist...
The treatment of Helicobacter pylori infection includes of current standard triple therapies consist...
Th e most popular regimen for eradication of Helicobacter pylori (H. pylori) infection is triple the...
Fourteen-day triple therapy with a proton pump inhibitor (PPI) plus clarithromycin and either amoxic...
H. pylori is one of the most common commensal microorganisms in the human body, colonizing up to 60%...
line depends on the treatment initially used. If a clarithro-mycin-based regimen was administered in...
The eradication of Helicobacter pylori is at present widely recognized as the adequate therapeutic a...
AbstractEradication of Helicobacter pylori infection has become an important issue recently, because...
Over the past 30 years, multidrug regimens consisting of a proton pump inhibitor (PPI) and two or th...
Helicobacter pylori infection, which is present in 30-60% of the population in developed countries a...
Over the past 30 years, multidrug regimens consisting of a proton pump inhibitor (PPI) and two or th...
Helicobacter pylori infection has many different clinical outcomes. Not all infected persons need to...
Helicobacter pylori (H. pylori) is currently considered the most important exogenous factor in the g...
Over the past 30 years, multidrug regimens consisting of a proton pump inhibitor (PPI) and two or th...
Helicobacter pylori, a Gram-negative organism that survives in the deep mucus layer and attaches to ...